Erdosteine for COPD exacerbations. -

Erdosteine for COPD exacerbations.

Abstract	The mucolytic drug erdosteine (Erdotin - Galen) is licensed in the UK as treatment for up to 10 days "for the symptomatic treatment of acute exacerbations of chronic bronchitis in adults". This indication differs from that for carbocisteine and mecysteine, two older mucolytic drugs that are licensed for adjunctive treatment in respiratory disorders characterised by viscous mucus, and typically used for longer to prevent exacerbations of chronic obstructive pulmonary disease (COPD). Does erdosteine have a role for people with COPD exacerbations?
Authors
Journal	Drug and therapeutics bulletin (Drug Ther Bull) Vol. 46 Issue 10 Pg. 79-80 (Oct 2008) ISSN: 0012-6543 [Print] England
PMID	18832259 (Publication Type: Journal Article)
Chemical References	Anti-Bacterial Agents Drug Combinations Expectorants Thioglycolates Thiophenes erdosteine
Topics	Adult Anti-Bacterial Agents (therapeutic use) Drug Combinations Expectorants (therapeutic use) Humans Pulmonary Disease, Chronic Obstructive (drug therapy) Randomized Controlled Trials as Topic Thioglycolates (therapeutic use) Thiophenes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!